Human Immunodeficiency Virus Organ Transplantation

Taege, Alan J.

doi:10.1016/j.idc.2018.04.013

Cited by 4 publications

(3 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our definition of pharmacotherapeutic interventions and their relevance in the pharmaceutical care of SOT recipients were based on the American Society of Health-System Pharmacists Guidelines on Pharmacy Services in Solid Organ Transplantation and HIV Care 22 and recent reviews on the management of SOT in PLWHIV. 8 , 23 , 24 All described interventions and recommendations for practice regarding drug therapy management were considered as pharmacotherapeutic interventions. More specifically, interventions on drug therapy for HIV, transplantation and SOT-related infectious and noninfectious complications were extracted based on a predefined framework (Figure 1 ).…”

Section: Methodsmentioning

confidence: 99%

Pharmacotherapeutic Interventions in People Living With HIV Undergoing Solid Organ Transplantation: A Scoping Review

Lam

Moussa

Sakr

et al. 2023

Transplantation Direct

View full text Add to dashboard Cite

Background. The pharmacotherapeutic management of people living with HIV (PLWHIV) undergoing solid organ transplantation (SOT) is clinically challenging, mainly due to the frequent occurrence of complex drug–drug interactions. Although various strategies have been proposed to improve treatment outcomes in these patients, several uncertainties remain, and consensus practice guidelines are just beginning to emerge. The main objective of this scoping review was to map the extent of the literature on the pharmacotherapeutic interventions performed by healthcare professionals for PLWHIV undergoing SOT. Methods. We searched Medline, Embase, and the Cochrane databases as well as gray literature for articles published between January 2010 and February 2020. Study selection was performed by at least 2 independent reviewers. Articles describing pharmacotherapeutic interventions in PLWHIV considered for or undergoing SOT were included in the study. Results. Of the 12 599 references identified through our search strategy, 209 articles met the inclusion criteria. Results showed that the vast majority of reported pharmacotherapeutic interventions concerned the management of immunosuppressive and antimicrobial therapy, including antiretrovirals. Analysis of the data demonstrated that for several aspects of the pharmacotherapeutic management of PLWHIV undergoing SOT, there were differing practices, such as the choice of immunosuppressive induction and maintenance therapy. Other important aspects of patient management, such as patient counseling, were rarely reported. Conclusions. Our results constitute an extensive overview of current practices in the pharmacotherapeutic management of SOT in PLWHIV and identify knowledge gaps that should be addressed to help improve patient care in this specific population.

show abstract

Section: Methodsmentioning

confidence: 99%

Pharmacotherapeutic Interventions in People Living With HIV Undergoing Solid Organ Transplantation: A Scoping Review

Lam

Moussa

Sakr

et al. 2023

Transplantation Direct

View full text Add to dashboard Cite

show abstract

“…HIV positive patients have barriers to being listed for transplant that HIV negative candidates do not have to face. Providers need to establish that candidates on ART have well controlled HIV based on CD4 counts (minimum CD4 count >200cells/mm 3 for kidneys and >100cells/mm 3 for livers) and viral loads [25]. In a 2009 single-center, retrospective review of 309 HIV positive patients who were eligible for kidney transplant evaluation, only 20% were listed for transplant compared to 73% of HIV-negative patients (p<0.00001) [26].…”

Section: Hivmentioning

confidence: 99%

New Frontiers in Solid Organ Transplantation from Donors with Human Immunodeficiency Virus, Hepatitis C Virus Infection, and Multidrug Resistant Organisms

Lum¹,

Mossad²

2018

obm transplant

View full text Add to dashboard Cite

show abstract

“…With the introduction and effectiveness of HAART therapy, the outcomes of HIV-positive recipients with ESLD are reportedly similar to HIV-negative recipients after LT[ 19 ]. However, the incompatibility between the ABO blood group and living organ donation severely limits the transplantation opportunities for this patient population[ 20 ]. Besides, LT in HIV patients using ABOi organs brings additional complexity and difficulty to this already intricate patient population.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus

Tang¹,

Zhang²,

Fang³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

BACKGROUND Human immunodeficiency virus (HIV)-positive patients coinfected with hepatitis B virus (HBV) are eligible for liver transplantation (LT) in Africa and Southeast Asia, particularly China. However, the outcome of HIV-HBV coinfected patients referred for ABO-incompatible LT (ABOi-LT) is unknown. AIM To clarify the outcome of ABOi-LT for HIV-HBV coinfected patients with end-stage liver disease (ESLD). METHODS We report on two Chinese HIV-HBV coinfected patients with ESLD who underwent A to O brain-dead donor LT and reviewed the literature on HIV-HBV coinfected patients treated with ABO-compatible LT. The pretransplantation HIV viral load was undetectable, with no active opportunistic infections. Induction therapy consisted of two sessions of plasmapheresis and a single dose of rituximab in two split doses, followed by an intraoperative regimen of intravenous immunoglobulin, methylprednisolone, and basiliximab. Post-transplant maintenance immunosuppressive agents consisted of tacrolimus and mycophenolate mofetil, and prednisone. RESULTS At the intermediate-term follow-up, patients showed undetectable HIV viral load, CD4(+) T cell counts greater than 150 cells/μL, no HBV recurrence, and stable liver function. A liver allograft biopsy showed no evidence of acute cellular rejection. Both patients survived at 36-42 mo of follow-up. CONCLUSION This is the first report of ABOi-LT in HIV-HBV recipients with good intermediate-term outcomes, suggesting that ABOi-LT may be feasible and safe for HIV-HBV coinfected patients with ESLD.

show abstract

Human Immunodeficiency Virus Organ Transplantation

Cited by 4 publications

References 82 publications

Pharmacotherapeutic Interventions in People Living With HIV Undergoing Solid Organ Transplantation: A Scoping Review

Pharmacotherapeutic Interventions in People Living With HIV Undergoing Solid Organ Transplantation: A Scoping Review

New Frontiers in Solid Organ Transplantation from Donors with Human Immunodeficiency Virus, Hepatitis C Virus Infection, and Multidrug Resistant Organisms

Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus

Contact Info

Product

Resources

About